SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
OtherPhase IVendors pending
Phase IVendors pendingFacts verified · 2026-05-25

SLU-PP-332 (oral tablets)

Also known as SLU-PP-332 (Tablets), pan-err agonist, errα/β/γ agonist · Wikipedia

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma) developed at Saint Louis University and described by Billon and colleagues as an exercise mimetic. In rodent studies it increases mitochondrial biogenesis, oxidative skeletal muscle fiber composition, treadmill endurance, fatty-acid oxidation, and insulin sensitivity without exercise. It is NOT a peptide - it is a benzimidazole-class small molecule - and the tablet form sold by research chemical vendors has no published human pharmacokinetic, efficacy, or safety data. All hype in fitness and biohacking communities outstrips the evidence.

—

best

price

—

per

mg

—

vendors

tracked

Phase I

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

SLU-PP-332 is a synthetic small-molecule pan-agonist of the three estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma) with highest potency at ERRalpha (https://pmc.ncbi.

SLU-PP-332 is a synthetic small-molecule pan-agonist of the three estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma) with highest potency at ERRalpha (https://pmc.ncbi.nlm.nih.gov/articles/PMC11584170/). ERRs are orphan nuclear receptors that, when activated by PGC-1alpha during exercise, drive transcription of mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and angiogenesis gene programs in skeletal muscle, heart, and adipose tissue. By directly binding and stabilizing the active conformation of the ERR ligand-binding domain, SLU-PP-332 mimics the transcriptional consequences of endurance exercise without contraction itself (https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/). In mice it increases mitochondrial density, type IIa oxidative fiber abundance, treadmill running time, and fat oxidation, and reduces fat mass accumulation. Despite being widely cited in the popular press, it has not entered human trials.

Pharmacokinetic properties

Half-life

limited published data; rodent studies suggest short plasma half-life (hours) with high doses required for sustained effect

Routes

oral

Bioavailability

Small molecule with moderate oral bioavailability in rodents (~20-30%). No published human PK data.

Amino-acid sequence

(Not a peptide; pan-ERR agonist small molecule)

Use & research dosing

Exercise-MimeticMitochondrial SupportFat OxidationEnergy

No human dose is established. Rodent studies used 50 mg/kg intraperitoneally daily, equivalent in mice to high systemic exposure. Oral bioavailability in animals is modest and no human PK exists. Online self-experimentation reports cite 10-50 mg oral daily for the tablet form, but these doses are entirely speculative, have no validated efficacy threshold, and are not supported by any clinical pharmacology data. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Not a peptide. Almost all efficacy evidence comes from rodent studies at Saint Louis University (Billon et al. and follow-on optimization work). Zero registered human clinical trials. Hype in fitness and longevity communities far exceeds the evidence base, and oral bioavailability for the tablet form is unstudied in humans. Marketplace 'tablets' from research-chemical vendors should be treated with very high skepticism for both identity and purity, and any claim of human efficacy at any specific dose is unsupported.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not a peptide - benzimidazole small molecule; should not be lumped with peptide safety considerations
  • Zero published human safety or efficacy data of any kind
  • ERR receptors are central to cardiac and skeletal muscle metabolism; chronic activation effects are unknown
  • Theoretical risk of cardiac remodeling with sustained ERRalpha activation
  • Unknown interactions with hormone-sensitive tissues; ERRs do not bind estrogen but share coregulators
  • Pregnancy and breastfeeding - avoid; no developmental toxicity data
  • All current tablets are research chemicals from unregulated sources with no identity or purity guarantees
  • Doping-control labs have already developed assays; flagged as a likely WADA-relevant compound

Research foundation

The papers behind the page.

  1. [01]https://pmc.ncbi.nlm.nih.gov/articles/PMC11584170/
  2. [02]https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/
  3. [03]https://pmc.ncbi.nlm.nih.gov/articles/PMC12277287/

Facts verified

2026-05-25

Confidence

low

What this means

  • not a peptide - small molecule or other compound on the marketplace
  • no human clinical data

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.